MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Soligenix, Inc. - Common Stock (NQ:SNGX)

1.370 -0.070 (-4.86%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 227,971
Open 1.390
Bid (Size) 1.360 (8,800)
Ask (Size) 1.380 (200)
Prev. Close 1.440
Today's Range 1.370 - 1.440
52wk Range 1.090 - 6.230
Shares Outstanding 3,504,950
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Soligenix Inc. (NASDAQ: SNGX) Extends SGX302 Clinical Success in Phase 2A Psoriasis Study
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Advances Ricin Vaccine amid Toxin Threat
Via Investor Brand Network

Performance

YTD
-53.4%
-53.4%
1 Month
-13.8%
-13.8%
3 Month
+23.4%
+23.4%
6 Month
+4.6%
+4.6%
1 Year
-52.6%
-52.6%

More News

Read More
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Publishes Positive Phase 2a SGX945 Data in Behçet’s Disease
Via Investor Brand Network
Chronic Inflammation Could Be the Missing Key to Understanding Long Covid
Via Investor Brand Network
NetworkNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Reports Extended Phase 2a Results for SGX302 Gel in Mild-to-Moderate Psoriasis
Via Investor Brand Network
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Featured in NetworkNewsAudio APR on Urgent Need for Rare Disease Therapies
Via Investor Brand Network
US to End Mandatory Vaccination of Newborns Against Hepatitis B
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Receives Strong Vote of Confidence from Zacks Report Despite Muted Market Response to Clinical Milestone
Via Investor Brand Network
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Featured in BioMedWire Editorial on Rare Disease Therapies
Via Investor Brand Network
News headline image
Soligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad
From Soligenix, Inc.
Via GlobeNewswire
Breakthrough Therapies Advance as Rare Disease Burden Intensifies Across Aging Populations
Via Investor Brand Network
Topics Government
News headline image
Breakthrough Therapies Advance as Rare Disease Burden Intensifies Across Aging Populations
From BioMedWire
Via GlobeNewswire
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Featured in BioMedWire Editorial Highlighting HyBryte(TM) and Rare Disease Policy
Via Investor Brand Network
News headline image
Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space
From Soligenix, Inc.
Via GlobeNewswire
Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now
Via Investor Brand Network
Topics Government
News headline image
Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now
From BioMedWire
Via GlobeNewswire
Soligenix Inc. (NASDAQ: SNGX) Reaches Key Enrollment Milestone in Phase 3 Trial with Encouraging Blinded Response Rate
Via Investor Brand Network
Study Uncovers Surprising Connection Between Choline, Obesity and Brain Inflammation
Via Investor Brand Network
MissionIRNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Advancing Heat-Stable Vaccine Platform with New Peer-Reviewed Data
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Elevates Advisory Network as Rare Disease Strategy Advances
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Strengthens CTCL Program as DMC Flags No Safety Issues
Via Investor Brand Network
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Completes Enrollment for Interim Analysis in Phase 3 FLASH2 Study of HyBryte
Via Investor Brand Network
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Completes Enrollment for Interim Analysis in Phase 3 FLASH2 Study of HyBryte
Via Investor Brand Network
Parent Explains Why it is Wrong to Say Vaccines Cause Autism
Via Investor Brand Network
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Highlights Key Clinical Progress and Reports Q3 2025 Financial Results
Via Investor Brand Network

Frequently Asked Questions

Is Soligenix, Inc. - Common Stock publicly traded?
Yes, Soligenix, Inc. - Common Stock is publicly traded.
What exchange does Soligenix, Inc. - Common Stock trade on?
Soligenix, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Soligenix, Inc. - Common Stock?
The ticker symbol for Soligenix, Inc. - Common Stock is SNGX on the Nasdaq Stock Market
What is the current price of Soligenix, Inc. - Common Stock?
The current price of Soligenix, Inc. - Common Stock is 1.370
When was Soligenix, Inc. - Common Stock last traded?
The last trade of Soligenix, Inc. - Common Stock was at 12/26/25 04:00 PM ET
What is the market capitalization of Soligenix, Inc. - Common Stock?
The market capitalization of Soligenix, Inc. - Common Stock is 4.80M
How many shares of Soligenix, Inc. - Common Stock are outstanding?
Soligenix, Inc. - Common Stock has 5M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story